A Study to Assess the Safety of TPM502 in Adults With Celiac Disease

NCT ID: NCT05660109

Last Updated: 2025-12-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-12-12
• Study Completion Date: 2024-08-08

Brief Summary

The goal of this clinical trial is to learn about the safety and the pharmacodynamic (PD) effects of TPM502 in adults with celiac disease. The main questions it aims to answer are:

• if TPM502 is safe and well tolerated
• if TPM502 can induce modifications in parameters indicating that it may induce tolerance to gluten

Participants will:

• undergo 1-day gluten challenge during screening and after administration of TPM502 or placebo.
• receive 2 infusions of TPM502 or placebo, 2 weeks apart

Detailed Description

This is a multi center, double-blind, randomized, placebo-controlled Phase 2a study to evaluate the safety, tolerability, and PD effects of two infusions of TPM502 in adult patients diagnosed with CeD.

The patient´s participation in the study comprises 3 phases: screening period, treatment period and follow-up period.

Patients fulfilling the eligibility criteria will be randomized to receive two infusions of TMP502 (or placebo) at the same dose level. Patients will undergo a second GC one week after the second infusion of TPM502.

The study includes 4 cohorts of patients, each cohort will receive escalating doses of TPM502 (or placebo). Upon completion of the 3rd cohort, a lower dose can be investigated, if deemed relevant.

Conditions

Celiac Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

TPM502

Group Type: EXPERIMENTAL

TPM502

Intervention Type: DRUG

TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5

placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo

Interventions

TPM502

TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Availability of a documented biopsy-confirmed diagnosis of CeD OR documented tissue transglutaminase >10x ULN and documented positive IgA anti-endomysial antibody (EMA) at time of CeD diagnosis (as per local guidelines)
• Serum anti-tissue transglutaminase 2 immunoglobin A antibodies within normal range (i.e., <15 U/mL) at screening
• Serum IL-2 levels (AUC1-6h) above a pre-defined threshold following the GC at screening
• Patients must have been on GFD for ≥ 6 months
• Patients must have well-controlled CeD, defined as mild or with no ongoing signs or symptoms felt to be related to active CeD, as per investigator's assessment
• HLA-DQ2.5 positive

Exclusion Criteria

• Known or suspected refractory CeD (refractory CeD type I or II)
• Known intolerable symptoms following previous GCs, as per investigator's assessment
• HLA DQ8 positive
• Any active gastrointestinal disease such as gastroesophageal reflux disease, esophagitis or peptic ulcer, microscopic colitis, or irritable bowel syndrome, which in the opinion of the investigator might interfere with the assessment of the symptoms related to CeD
• Known history of or active Crohn's disease, ulcerative colitis, or ulcerative jejunitis
• Known wheat allergy
• Known hypersensitivity to i.v. iron preparations or any other excipients present in the reconstituted TPM502 or placebo

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Topas Therapeutics GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Knut Lundin, MD

Role: PRINCIPAL_INVESTIGATOR

Oslo University Hospital

Locations

Royal Adelaide Hospital

Adelaide, , Australia

Wesley Research Institute

Brisbane, , Australia

CRST Oy

Turku, , Finland

Charite' Hospital

Berlin, , Germany

Centre for Human Drug Research

Leiden, , Netherlands

Oslo University Hospital HF - Rikshospitalet

Oslo, , Norway

University Hospital of North-Norway

Tromsø, , Norway

Clinical Trial Consultants, Uppsala University

Uppsala, , Sweden

Countries

Australia; Finland; Germany; Netherlands; Norway; Sweden

Other Identifiers

TCeD21

Identifier Type: -

Identifier Source: org_study_id